Palo Alto, CANCT06237335Now EnrollingIRB Ready

Cystic Fibrosis Clinical Trial in Palo Alto, CA

Access cutting-edge cystic fibrosis treatment through this clinical trial at a research site in Palo Alto. Study-provided care at no cost to qualified participants.

Sponsored by ReCode Therapeutics

Quick Self-Assessment

See if you qualify for this Palo Alto location

Preparing your pre-screening questions…

Expert Care in Palo Alto

Access cystic fibrosis specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related cystic fibrosis treatment provided free

Apply for This Palo Alto Location

Check if you qualify for this cystic fibrosis clinical trial in Palo Alto, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Palo Alto

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Palo Alto site if eligible
  4. 4Begin participation

About This Cystic Fibrosis Study in Palo Alto

This is the first-in-human study with RCT2100 and is designed to provide safety and tolerability data for future clinical studies.

Sponsor: ReCode Therapeutics

Who Can Participate

Inclusion Criteria

Healthy, adult, male or female, 18-55 years of age, inclusive, at screening.
Body weight greater than or equal to 50 kg and body mass index (BMI) between 16-32 kg/m2, inclusive
The participant has a forced expiratory volume in one second (FEV1) of at least 80% predicted
The participant is considered by the investigator to be in good general health as determined by medical history, clinical laboratory test results, vital sign measurements, 12-lead ECG results, and physical examination findings at screening.
Understands the study procedures in the informed consent form (ICF), and is willing and able to comply with the protocol. Part 1 Major

Exclusion Criteria

History or presence of clinically significant medical, surgical, clinical laboratory, or psychiatric condition or disease.
The participant has supine blood pressure (BP) \>150 mm Hg (systolic) or \>90 mm Hg (diastolic), following at least 5 minutes of supine rest.
The participant has abnormal clinical laboratory tests at screening, as assessed by the study-specific laboratory.
The participant is a smoker or has used nicotine or nicotine-containing products 6 weeks before the first dose of study drug. Former smokers with greater than 10 pack years of smoking history are excluded. Part 2 Major Inclusion Criteria:
Confirmed diagnosis of CF
Forced expiratory volume in 1 second ≥50% and ≤100% of predicted mean value for age, sex, and height
a) Not eligible for CFTR modulators based on having mutations of CFTR gene on both alleles that are not responsive to CFTR modulator therapy OR
b) Eligible for CFTR modulators (based on local prescribing information) but not using CFTR modulators due to intolerance or contraindications Part 2 Major Exclusion Criteria:
Hepatic cirrhosis with portal hypertension, moderate hepatic impairment (Child Pugh Score 7 to 9), or severe hepatic impairment (Child Pugh Score 10 to 15)
An acute upper or lower respiratory infection, pulmonary exacerbation, or changes in therapy (including antibiotics) for sinopulmonary disease within 4 weeks before the first dose of study drug
Lung infection with organisms associated with a more rapid decline in pulmonary status
Arterial oxygen saturation on room air less than 94% at screening
Treatment with a CFTR modulator (Kalydeco, Trikafta, Symdeko, Orkambi, or Alyftrek) within 12 weeks of Screening Other protocol defined Inclusion/Exclusion criteria may apply. Part 3 Major Inclusion Criteria:
Confirmed diagnosis of CF
Forced expiratory volume in 1 second ≥50% and ≤100% of predicted mean value for age, sex, and height
a) Not eligible for CFTR modulators based on having mutations of CFTR gene on both alleles that are not responsive to CFTR modulator therapy OR
b) Eligible for dual or triple CFTR modulators (based on local prescribing information) but not using CFTR modulators due to intolerance or contraindications Part 3 Major Exclusion Criteria:
Hepatic cirrhosis with portal hypertension, moderate hepatic impairment (Child Pugh Score 7 to 9), or severe hepatic impairment (Child Pugh Score 10 to 15)
An acute upper or lower respiratory infection, pulmonary exacerbation, or changes in therapy (including antibiotics) for sinopulmonary disease within 4 weeks before the first dose of study drug
Lung infection with organisms associated with a more rapid decline in pulmonary status
Arterial oxygen saturation on room air less than 94% at screening
Treatment with a CFTR modulator (Kalydeco, Trikafta, Symdeko, Orkambi, or Alyftrek) within 12 weeks of Screening Other protocol defined Inclusion/Exclusion criteria may apply.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Palo Alto?

Yes, this clinical trial (NCT06237335) has an active research site in Palo Alto, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Cystic Fibrosis Treatment Options in Palo Alto, CA

If you're searching for cystic fibrosis treatment options in Palo Alto, CA, this clinical trial (NCT06237335) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Palo Alto research site is actively enrolling participants for this clinical trial. You'll receive care from experienced cystic fibrosis specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all cystic fibrosis clinical trials near you to find additional studies recruiting in your area.

More Cystic Fibrosis Trials in Palo Alto, CA

See all cystic fibrosis clinical trials recruiting in Palo Alto — not just this study.

Browse Cystic Fibrosis Trials in Palo Alto →

Browse More Trials by Condition

Cystic Fibrosis TrialsInterstitial Cystitis TrialsFibromyalgia TrialsAll Conditions →

Ready to Join in Palo Alto?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Palo Alto, CA